Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 4/20 | 0.34 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.33 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL565222 | 0.38 | CYP1A2 (0.47) | GAAGFERALDH1A1KMT2A | |
| SCHEMBL1069 | 0.38 | — | — | |
| SCHEMBL5127 | 0.36 | — | — | |
| SCHEMBL14938 | 0.33 | — | — | |
| SCHEMBL898958 | 0.30 | — | — | |
| Methane SCHEMBL23044967 | 0.27 | — | — | |
| SCHEMBL7658668 | 0.27 | — | — | |
| SCHEMBL3723878 | 0.27 | — | — | |
| SCHEMBL1261076 | 0.27 | — | — | |
| SCHEMBL10896230 | 0.27 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150038480-A1 | COMPOUNDS THAT MODULATE AUTOIMMUNITY AND METHODS OF USING THE SAME | UNIVERSITY OF FLORIDA RESERCH FOUNDATION INCORPORTED (US) | 2015-02-05 | — | — | US | claimed |
| US-9629848-B2 | Compounds that modulate autoimmunity and methods of using the same | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2017-04-25 | — | — | US | disclosed |
| US-9629848-B2 | Compounds that modulate autoimmunity and methods of using the same | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2017-04-25 | — | — | US | disclosed |
| US-9629848-B2 | Compounds that modulate autoimmunity and methods of using the same | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2017-04-25 | — | — | US | disclosed |
| US-9616051-B2 | Drug targets to overcome de novo drug-resistance in multiple myeloma | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9616051-B2 | Drug targets to overcome de novo drug-resistance in multiple myeloma | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9616051-B2 | Drug targets to overcome de novo drug-resistance in multiple myeloma | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20150038480-A1 | COMPOUNDS THAT MODULATE AUTOIMMUNITY AND METHODS OF USING THE SAME | UNIVERSITY OF FLORIDA RESERCH FOUNDATION INCORPORTED (US) | 2015-02-05 | — | — | US | disclosed |
| US-20150038480-A1 | COMPOUNDS THAT MODULATE AUTOIMMUNITY AND METHODS OF USING THE SAME | UNIVERSITY OF FLORIDA RESERCH FOUNDATION INCORPORTED (US) | 2015-02-05 | — | — | US | disclosed |
| US-20150038480-A1 | COMPOUNDS THAT MODULATE AUTOIMMUNITY AND METHODS OF USING THE SAME | UNIVERSITY OF FLORIDA RESERCH FOUNDATION INCORPORTED (US) | 2015-02-05 | — | — | US | disclosed |
| US-8623854-B2 | Nuclear export inhibitors of topoisomerase II alpha | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8623854-B2 | Nuclear export inhibitors of topoisomerase II alpha | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8623854-B2 | Nuclear export inhibitors of topoisomerase II alpha | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20130281389-A1 | NOVEL DRUG TARGETS TO OVERCOME DE NOVO DRUG-RESISTANCE IN MULTIPLE MYELOMA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2013-10-24 | — | — | US | disclosed |
| US-20130281389-A1 | NOVEL DRUG TARGETS TO OVERCOME DE NOVO DRUG-RESISTANCE IN MULTIPLE MYELOMA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2013-10-24 | — | — | US | disclosed |
| US-20130281389-A1 | NOVEL DRUG TARGETS TO OVERCOME DE NOVO DRUG-RESISTANCE IN MULTIPLE MYELOMA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2013-10-24 | — | — | US | disclosed |
| US-20110275581-A1 | NUCLEAR EXPORT INHIBITORS OF TOPOISOMERASE II ALPHA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275581-A1 | NUCLEAR EXPORT INHIBITORS OF TOPOISOMERASE II ALPHA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275581-A1 | NUCLEAR EXPORT INHIBITORS OF TOPOISOMERASE II ALPHA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038480-A1 | COMPOUNDS THAT MODULATE AUTOIMMUNITY AND METHODS OF USING THE SAME | HLA-DRB1, IAPP, CD74 | NOS1 1077/4885SIGMAR1 4447/4885GAA 180/4885 |
| US-20110275581-A1 | NUCLEAR EXPORT INHIBITORS OF TOPOISOMERASE II ALPHA | TOP2A, TOP1, XPOT | NOS1 1394/4885SIGMAR1 3322/4885GAA 2030/4885 |
| US-20130281389-A1 | NOVEL DRUG TARGETS TO OVERCOME DE NOVO DRUG-RESISTANCE IN MULTIPLE MYELOMA | XPO1, XPOT, DDB1 | NOS1 1434/4885SIGMAR1 1879/4885GAA 4074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.